Eric Goosby, MD

Professor of Clinical Medicine

HIV, Infectious Disease, and Global Medicine, Infectious Diseases

Education
M.D., 1978 - Medicine, University of California, San Francisco
Residency, - School of Medicine, University of California, San Francisco
Honors and Awards
  • Institute of Medicine Member, 2014
Publications
  1. Political prioritization and the competing definitions of adolescent pregnancy in Kenya: An application of the Public Arenas Model.
  2. Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer.
  3. Achieving Universal Health Coverage (UHC): Dominance analysis across 183 countries highlights importance of strengthening health workforce.
  4. Improving quality is necessary to building a TB-free world: Lancet Commission on Tuberculosis.
  5. Challenges to generating political prioritization for adolescent sexual and reproductive health in Kenya: A qualitative study.
  6. Employing the Payback Framework to Assess Implementation Science Research Utilization: Lessons From the USAID's PEPFAR HIV/AIDS Implementation Science Awards.
  7. Monitoring Universal Health Coverage (UHC) in high Tuberculosis burden countries: Tuberculosis mortality an important tracer of UHC service coverage.
  8. Global Fund replenishment brings us one step closer to ending tuberculosis.
  9. Improving the cascade of global tuberculosis care: moving from the "what" to the "how" of quality improvement.
  10. A tuberculosis-free world: is it a delusion? - Authors' reply.
  11. The Global Fund, Governance, and Accountability.
  12. The legal determinants of health: harnessing the power of law for global health and sustainable development.
  13. The HIV response and global health.
  14. Building a tuberculosis-free world: The Lancet Commission on tuberculosis.
  15. Leveraging health diplomacy to end the tuberculosis epidemic.
  16. To End TB, First-Ever High-Level Meeting on TB Must Address Stigma.
  17. Eradicating TB.
  18. Preventing tuberculosis among high-risk workers.
  19. Message to world leaders: we cannot end tuberculosis without addressing the social and economic burden of the disease.
  20. Building on the HIV platform: tackling the challenge of noncommunicable diseases among persons living with HIV.
  21. Have geopolitics influenced decisions on American health foreign assistance efforts during the Obama presidency?
  22. Global governance of antimicrobial resistance.
  23. The Lancet Commission on tuberculosis: building a tuberculosis-free world.
  24. Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.
  25. Crossing the Finish Line.
  26. Lessons learned from the HIV care cascade can help End TB.
  27. Children with TB: neglected no more . . ..
  28. Health impact of human rights testimony: harming the most vulnerable?
  29. Public health and international drug policy.
  30. Transforming Global Health by Improving the Science of Scale-Up.
  31. Out of the shadows: shining a light on children with tuberculosis.
  32. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola.
  33. Politics and Universal Health Coverage--The Post-2015 Global Health Agenda.
  34. Defeating AIDS--advancing global health.
  35. Maximizing the Impact of Training Initiatives for Health Professionals in Low-Income Countries: Frameworks, Challenges, and Best Practices.
  36. Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange.
  37. NCDs and an outcome-based approach to global health.
  38. The Medical and Nursing Education Partnership Initiatives.
  39. PEPFAR's commitment to country ownership and achieving an AIDS-free generation.
  40. The human resources for health program in Rwanda--new partnership.
  41. Foreword: Global action to reduce HIV stigma and discrimination.
  42. Global Action to reduce HIV stigma and discrimination.
  43. An inclusive rights-based foreign policy for health.
  44. Is Option B+ the best choice?
  45. US visa law: a clarification.
  46. Raising the bar: PEPFAR and new paradigms for global health.
  47. The United States President's Emergency Plan for AIDS Relief: a story of partnerships and smart investments to turn the tide of the global AIDS pandemic.
  48. The way forward: maximizing our impact through shared responsibility and smart investments.
  49. Community action to end new paediatric HIV infections.
  50. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response.
  51. PEPFAR's past and future efforts to cut costs, improve efficiency, and increase the impact of global HIV programs.
  52. The President's Emergency Plan for AIDS Relief: marshalling all tools at our disposal toward an AIDS-free generation.
  53. A call for coordinated and evidence-based action to protect children outside of family care.
  54. Implementation science for the US President's Emergency Plan for AIDS Relief (PEPFAR).
  55. Public health. Developing health workforce capacity in Africa.
  56. AIDS funds: prevention.
  57. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
  58. The Chinese free antiretroviral treatment program: challenges and responses.
  59. Needle exchange programs for the prevention of human immunodeficiency virus infection: epidemiology and policy.
  60. A Methodological Model for Rapid Assessment, Response, and Evaluation: The RARE Program in Public Health.
  61. Methodologically sound rapid assessment and response: providing timely data for policy development on drug use interventions and HIV prevention.
  62. Paronychia in patients receiving antiretroviral therapy for human immunodeficiency virus infection.
  63. Early treatment of HIV-1 infection.
  64. Primary HIV Infection/Acute Retroviral Syndrome: An Intervention Opportunity for Correctional Facilities.
  65. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial.
  66. Issues regarding antiretroviral treatment for patients with HIV-1 infection.
  67. The diagnostic laboratory as clinical consultant: public health implications.
  68. Inmate access to postrelease medical care: public health implications.
  69. Maintenance of chemoprophylaxis against Pneumocystis carinii despite combination antiretroviral treatment associated CD4+ T-lymphocytosis.
  70. Physicians' experience and survival in patients with AIDS.
  71. PCR and the misdiagnosis of active tuberculosis.
  72. Miles to go before we sleep.
  73. From the Health Resources and Services Administration.
  74. Only a Phone Call Away: Educating Health Care Professionals About HIV/ AIDS.
  75. Telephone information services from USPHS.
  76. Educating primary care providers about HIV disease: multidisciplinary interactive mechanisms.
  77. States' responses to Title II of the Ryan White CARE Act.
  78. First year of AIDS services delivery under Title I of the Ryan White CARE Act.
  79. Recovery of function after hip fracture. The role of social supports.
  80. Medical management of angina: nitrates, beta blockers, calcium channel blockers.